PREVYMIS 20 mg/mL (Letermovir INJECTION, SOLUTION) 20 mg/mL

Prevymis 20 mg/mL is an intravenous solution containing letermovir, used for managing certain medical conditions. This single-dose injection is designed for specific therapeutic applications, offering a convenient treatment option.

Strength

20 mg/mL

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (0006-5004-01) / 24 mL in 1 VIAL, SINGLE-DOSE (0006-5004-02)

Manufacturer / TM Owner

Merck Sharp & Dohme LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Prevymis 20 mg/mL is primarily used for managing conditions related to viral infections. This letermovir injection is often utilized in clinical settings to support treatment protocols. Patients and healthcare providers may explore what is Prevymis used for in more detail through professional consultation.

Side Effects

Common effects of Prevymis 20 mg/mL may include mild to moderate reactions at the injection site. Some individuals might experience general discomfort or fatigue. It's important to monitor any unusual symptoms and consult a healthcare provider if concerns arise.

Precautions & Warnings

Prevymis 20 mg/mL should be handled with care, ensuring proper storage and administration protocols are followed. Patients with known allergies to letermovir or similar compounds should exercise caution. Always follow the guidance of a healthcare professional when using this injection.

Avoid Interactions

Prevymis 20 mg/mL may interact with certain medications, particularly those metabolized by the liver. It's advisable to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and other substances may also affect the efficacy and safety of this treatment.

Frequently Asked Questions

Prevymis 20 mg/mL is used for managing certain viral infections, often in clinical settings.

Prevymis 20 mg/mL is administered intravenously, typically by a healthcare professional.

Common side effects may include mild to moderate reactions at the injection site and general discomfort.

Prevymis 20 mg/mL may interact with certain medications, so it's important to consult a healthcare provider.

Prevymis is available in a 20 mg/mL strength for intravenous administration.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.